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Background: Saturated fatty acids are thought to be of relevance for the development of non-alcoholic fatty liver
disease and obesity. However, the underlying mechanisms are poorly understood. In previous studies we found that
food-derived carbohydrates such as fructose alter the intestinal serotonergic system while inducing fatty liver
disease in mice. Here, we examined the effect of fatty acid quantity (11% versus 15%) and quality (saturated,
monounsaturated, or polyunsaturated fatty acids) on hepatic fat accumulation, intestinal barrier and the intestinal
serotonergic system.
Methods: C57BL/6 mice had free access to diets enriched with one of the three fatty acids or standard diet, for
8 weeks. In an additional experiment mice were fed diets enriched with saturated, monounsaturated fatty acids or
standard diet supplemented with tryptophan (0.4 g/(kg.d), 8 weeks) or not. Hepatic fat accumulation, small
intestinal barrier impairment and components of the serotonergic system were measured with RT-PCR, western blot
or immunoassays. For statistical analysis t-test and one-way ANOVA with Tukey’s post hoc test and Bartlett’s test for
equal variances was used.
Results: Hepatic triglycerides, liver weight and liver to body weight ratio were significantly changed depending on
the fat quality but not fat quantity. In contrast, fat quantity but not quality decreased the expression of the tight
junction proteins occludin and claudin-1 in the small intestine. These changes seemed to result in enhanced portal
vein endotoxin concentrations and fatty liver disease after feeding diet enriched with saturated and monounsaturated
fatty acids but not polyunsaturated fatty acids. Neither fatty acid quantity nor quality significantly influenced the
intestinal serotonergic system. Similarly, tryptophan supplementation had no impact on small intestinal barrier or fatty
liver disease.
Conclusion: In conclusion, diets rich in saturated or monounsaturated fatty acids promote the development of fatty
liver disease in mice, likely by a dysfunction of the small intestinal mucosal barrier.
Keywords: Non-alcoholic fatty liver disease, Saturated, Monounsaturated, Polyunsaturated fatty acids in diet, Serotonin,
Intestinal permeabilityBackground
Non-alcoholic fatty liver disease (NAFLD) is one of the
most important forms of liver disease in the developed
countries, occurring in 20% to 25% of the general popu-
lation [1,2]. Diet and lifestyle habits leading to obesity
and insulin resistance are believed to exert the main
pathophysiological role in the development of NAFLD
[3-5]. Among the dietary factors, high fat intake and
high sugar intake (“Western-style diet”) are thought to* Correspondence: bischoff.stephan@uni-hohenheim.de
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reproduction in any medium, provided the orbe of particular relevance [6]. In previous studies per-
formed in mice, we could show that within the sugars,
fructose plays a particular role for the development of
NAFLD, whereas glucose is more relevant with regard to
body weight [7]. Other studies suggested that a high fat
intake, for example saturated fatty acids (SFA), is critical
for both, the development of obesity and NAFLD [6,8,9].
In contrast, monounsaturated fatty acids (MUFA) and
polyunsaturated fatty acids (PUFA) have been attributed
rather to a healthy diet [10].
The mechanisms of diet-induced NAFLD are by far
not clear at present. Based on previously published studies,d. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of NAFLD development is an altered gastrointestinal (GI)
barrier function. GI barrier dysfunction may be caused by
particular diets or dietary components resulting in an im-
paired mucosal barrier and an elevated portal endotoxin
level [11]. The endotoxin enters the liver where it is recog-
nized by Toll-like receptors (TLR) and triggers innate
immune responses and inflammation [12-14]. Evidence is
increasing that high intake of dietary sugars may lead to
increased portal endotoxin levels and as a result activation
of TLRs [15]; however, the mechanisms by which high
intake of dietary fatty acids cause obesity and fatty liver
disease remain elusive.
Apart from the “translocation hypothesis”, stating that
an impaired GI barrier leads to translocation of endo-
toxin from the gut lumen to the liver and causing fatty
liver disease, other mechanisms might be considered. For
example, serotonin (5-HT) derived from enterochromaffin
cells, has been recognized as a potent pro-inflammatory
mediator [16] and major regulator of intestinal permea-
bility [14]. Interestingly, we could show that 5-HT is up-
regulated in mice fed a fructose-rich diet and that liver
steatosis induced by such a diet can be attenuated by sup-
pressing 5-HT signaling [17]. The precursor of 5-HT is
the amino acid tryptophan (TRP), which is also known to
be a regulator of intestinal motility [18,19]. TRP has been
used to alter the intestinal serotonin homeostasis, since
intra peritoneal treatment with TRP enhances 5-HT levels
[20,21]. Surprisingly, it also has been reported that TRPTable 1 Diet composition (% w/w)
w/w C C+ TRP
Casein % 23.00 23.00
Corn starch, pre-gelatinized % 34.90 34.90
Maltodextrin % 14.28 14.04
Sucrose % 5.20 5.20
Cellulose powder % 3.90 3.90
L-Cystine % 0.30 0.30
L-Tryptophan % ——– 0.24
Vitamin premix1 % 1.20 1.20
Mineral & trace element premix2 % 6.00 6.00
Choline chloride (50%) % 0.20 0.20
Butylated hydroxytoluene % 0.02 0.02
Soy oil % 11.00 11.00
Beef tallow % ——– ——–
Olive oil % ——– ——–
Safflower oil % ——– ——–
C, Control; SFA, saturated fatty acids; TRP, tryptophan; MUFA, monounsaturated fatt
1Vitamin premix supplied per kg of diet: retinol, 4.5 mg; cholecalciferol, 0.0375 mg;
30 mg; thiamin, 16 mg; riboflavin, 16 mg; pyridoxine, 18 mg; cobalamin, 0.03 mg; n
inositol, 80 mg.
2Mineral & trace element premix supplied per kg of diet: Fe, 162 mg as ferrous fum
14 mg as copper sulphate; I, 1.2 mg as calcium iodate, Se, 0.11 mg as sodium selenis capable of reducing hepatic lipid accumulation in par-
ticular animal models [22,23] and plasma triglycerides in
humans [24]. In addition, TRP is able to exert anti-
inflammatory effects in the liver [25].
Here, we studied potential mechanisms leading to the
development of diet-induced fatty liver disease. We fed
three types of fatty acid enriched diets with or without
TRP supplement and investigated the effect of these di-
ets on the intestinal barrier function, fatty liver disease
and the intestinal serotonergic system in mice.
Methods
Mice and treatments
Mice were housed in a pathogen-free barrier facility
accredited by the Association for Assessment and
Accreditation for Laboratory Animal Care International
(AAALAC). All procedures were approved by the local
Institutional Animal Care and Use Committee (Regional
Council Stuttgart). Female 6 weeks old C57BL/6 mice
(Janvier, Le-Genes-St-isle, France) had ad libitum access,
for 8 weeks, to either a modified (11% fat) standard diet
(MZ-Ereich, Sniff®-Spezialdiäten GmbH, Soest, Germany)
as control (C; 17.2 kJ/g diet) or 3 different diets enriched
with fatty acids (15%) either SFA (beef tallow), MUFA
(olive oil with a 14.4:1.6:1(n-9), (n-6), (n-7) fatty acid
ratio), or PUFA (safflower oil with a 6:2 (n-6), (n-9) fatty
acid ratio; n = 5 mice per group) (Table 1). The diets
enriched with fatty acids were iso-energetic with
17.6 kJ/g diet (Table 2). In an additional experimentSFA SFA +TRP MUFA MUFA + TRP PUFA
24.00 24.00 24.00 24.00 24.00
30.00 30.00 30.00 30.00 30.00
8.28 8.04 8.28 8.04 8.28
10.00 10.00 10.00 10.00 10.00
5.00 5.00 5.00 5.00 5.00
0.30 0.30 0.30 0.30 0.30
——– 0.24 ——– 0.24 ——–
1.20 1.20 1.20 1.20 1.20
6.00 6.00 6.00 6.00 6.00
0.20 0.20 0.20 0.20 0.20
0.02 0.02 0.02 0.02 0.02
——– ——– ——– ——– ——–
15.00 15.00 ——– ——–
——– ——– 15.00 15.00 ——–
——– ——– ——– ——– 15.00
y acids; PUFA, polyunsaturated fatty acids.
all-rac (DL-) α-tocopherol, 150 mg; menadione (as MNB), 20 mg; L-ascorbic acid,
iacin, 49 mg; D-pantothenic acid, 56 mg; folic acid, 19 mg; D-biotin, 0.31 mg;
arate; Mn, 98 mg as manganese sulphate; Zn, 64 mg as zinc sulphate; Cu,
ite; and Co, 0.12 mg as cobalt carbonate.
Table 2 Fatty acid composition of the different experimental diets (% wt/wt)
Fatty acids wt/wt Soy oil (C) Beef tallow (SFA) Olive oil (MUFA) Safflower oil (PUFA)
Energy content (kJ/g) % 17.2 17.6 17.6 17.6
C 12:0 % - 0.02 - -
C 14:0 % 0.01 0.5 0.01 0.01
C 16:0 % 1.25 3.76 1.65 0.98
C 16:1 % 0.01 - - -
C 18:0 % 0.45 2.65 0.43 0.37
C 18:1 % 2.30 5.50 10.44 1.59
C 18:2 % 5.13 0.38 1.24 11.27
C 18:3 % 0.79 - - -
C 20:0 % 0.03 - - -
Others1 % 1.03 1.60 1.39 0.62
Σ SFA % 1.74 7.14 1.75 1.45
Σ MUFA % 2.31 5.88 10.62 1.66
Σ PUFA % 5.92 0.38 1.24 11.27
Abbreviations: C, Control; SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids. 1Not specified fatty acids.
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Sniff®-Spezialdiäten GmbH, Soest, Germany), the modi-
fied standard diet enriched with TRP (about 0.4 g/kg
body weight); 0.24% w/w; C + TRP), a diet enriched with
SFA or MUFA supplemented with TRP or not (n = 6
mice per group). The amount of TRP administered was
selected according to Rogers et al. [23] (Table 1). Body
weight, diet and fluid intake were assessed weekly. After
8 weeks, mice were anesthetized [7]. Blood was col-
lected from the portal vein prior to killing. Small in-
testinal motility was assessed by the charcoal test. A
charcoal solution (0.5 g charcoal; 0.25 g gum arabic;
5 ml 0.9% NaCl) (body weight in g x 15 = Volume of
charcoal solution in μL) was administered intra gastric,
by gavage, 10 min before killing, and migration of char-
coal solution from the pylorus along the small intestine
was measured. The small intestine was removed and
gently, without tension, stretched. The migration of the
charcoal was measured with a ruler. Intestinal and liver
tissue was snap-frozen for RNA and protein extraction.
Hepatic lipid analysis and histology
Liver tissue pieces (50–100 mg) were homogenized in
ice-cold 2x PBS and lipids were extracted. Triglycerides
were assessed with a kit (Randox, Krefeld, Germany).
Values were normalized to protein concentration, deter-
mined by Bradford assay, in liver homogenates (Bio-Rad
Laboratories, Munich, Germany).
To determine hepatic lipid accumulation, frozen sec-
tions of liver (10 μm) were stained with Oil Red O and
counterstained with haematoxylin (Sigma, Steinheim,
Germany). Representative photomicrographs were cap-
tured at a 400x magnification using Axio Vert 200 M,
(Zeiss, Jena, Germany).Liver histology was assessed in liver sections using
haematoxylin and eosin staining.
Endotoxin assay
Portal plasma samples were heated at 73°C for 20 min.
Endotoxin levels were determined using a limulus ame-
bocyte lysate assay kit (concentration range of 0.015–1.2
EU/mL)(Charles River, Wilmington, MA).
Protein expression and gene expression
Protein was prepared and antibodies were applied as de-
scribed earlier [17]. Semi-quantitative real-time PCR
analyses were performed using SsoFast EvaGreen Super-
mix (BioRad Laboratories, Munich, Germany) and were
carried out in an iCycler (BioRad Laboratories, Munich,
Germany) with 40 cycles of a two-step PCR (denaturation
95°C for 35 s, denaturation 95°C for 5 s, annealing/exten-
sion 62°C for 10 s). MyD88, TNF-α and β-actin primer
sequences were used as previously described [17]. Trypto-
phan hydroxylase 1 (THP1) primer sequence: forward
CAT CAG CCG AGA ACA GTT GA; reverse TTC GGA
TCC ATA CAA CAG CA.
Measurement of the serotonin content in the duodenum
Frozen duodenum was homogenized in 0.05 M HCL with
0.1% ascorbic acid. 5-HT content (in ng/mg weight) was
determined using an enzyme immunoassay kit (sensitivity
2.68 ng/mL) (IBL, Hamburg, Germany).
Statistical analyses
All results are presented as means ± SEM. Effects of fat
quantity in the diet were evaluated by comparing the re-
sults in the control group receiving an 11% fat diet with
those in the fatty acid enriched groups receiving 15% fat
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the means of the combined fatty acid enriched groups
were calculated and compared using the t-test, or t-test
with the Welch’s correction, if variances differed signifi-
cantly. One-way ANOVA analysis and Tukey’s post hoc
test or Bartlett’s test for equal variances was used to
compare the fat quality within the three groups receiving
fatty acid enriched diets (SFA, MUFA, PUFA). One-way
ANOVA was also used to analyze the effects of TRP in
animals receiving either SFA or MUFA enriched diets. If
the Bartlett’s test showed no equal variances, the Kruskal









Figure 1 Saturated fatty acids increase fatty acid accumulation in the
Liver weight (B), final body weight (C) and liver to body ratio (D) are shown. O
(E). Haematoxylin eosin staining shows liver histology (F). aP < 0.05 ANOVA res
SFA. Means ± SEM, n= 5. Abbreviations: C, control; SFA, saturated fatty acids; MUvalue < 0.05 was determined as the level of significance
prior to study start. The software GraphPad Prism 5
(GraphPad Software, La Jolla, CA) was used for calcula-
tion and graph design.
Results
Fatty acids affect fat accumulation in the liver
Enhancing the fat content in the diet from 11% to 15%
did not change significantly hepatic triglyceride levels.
However, fat quality had a pronounced effect. SFA diet,
compared to PUFA and to MUFA diet, caused higher





liver. Triglycerides (A) were measured with a colorimetric kit in the liver.
il-Red-O staining shows representative fatty acid accumulation in the liver
ult for the effect of the MUFA diet compared to SFA; bPUFA compared to
FA, monounsaturated fatty acids; PUFA, polyunsaturated fatty acids.
Table 3 Effect of fatty acids on food and water intake as well as intestinal motility
Diets C SFA MUFA PUFA
n 5 5 5 5
Food intake (kcal/wk) 63.77 ± 0.43 80.52 ± 2.36 70.43 ± 1.63a 79.32 ± 1.34b
Water intake (ml/wk) 25.61 ± 0.19*** 16.97 ± 0.40 16.92 ± 0.41 22.58 ± 0.29a,b
Intestinal motility (distance in cm) 8.72 ± 2.06 14.78 ± 1.57 11.70 ± 2.35 14.14 ± 2.20
Means ± SEM from n = 5 mice per group. aP < 0.05 food intake compared to SFA, bP < 0.05, food intake compared to MUFA. ***P < 0.001 water intake compared to
mean of fatty acid enriched diet groups. a,bP < 0.01 water intake compared to SFA and MUFA. Abbreviations: C, Control; SFA, saturated fatty acids; MUFA,
monounsaturated fatty acids; PUFA, polyunsaturated fatty acids.
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weight was not influenced in mice fed the SFA, MUFA
or PUFA diet (Figure 1C), we measured an increased
liver to body weight ratio (P < 0.01, Figure 1D). We sup-
ported our results with representative staining of fatA
C
E
Figure 2 Influence of fatty acids on portal endotoxin, hepatic MyD88
concentration (A) and MyD88 mRNA concentration (B) in the liver are sho
in the small intestine with quantitative analysis of protein expression are show
compared to SFA, ccompared to MUFA. Means ± SEM, n = 5. Abbreviations: C,
PUFA, polyunsaturated fatty acids; MyD88, myeloid differentiation primary respaccumulation in the liver, showing an increase in hepatic
fat feeding SFA or MUFA compared to PUFA enriched
or control diet (Figure 1E). In addition, we observed a
higher degree of steatosis and ballooning cells in SFA
fed mice compared to a lower degree of steatosis andB
D
F
and intestinal tight junction proteins. Portal endotoxin
wn. Representative western blots of occludin (C/E) and claudin-1 (D/F)
n. aP < 0.05 ANOVA result for effect of different diets compared to C; b
control; SFA, saturated fatty acids; MUFA, monounsaturated fatty acids;
onse gene 88.
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pearance in PUFA fed mice (Figure 1F). However, mice
fed with the PUFA enriched diet had a similar elevated
food intake as mice fed with the SFA enriched diet in
contrast to MUFA fed mice (P < 0.05, Table 3). Overall
water intake was reduced due to fat quantity. Mice fed
the diets enriched with fatty acids drank less water com-
pared to the control group (P < 0.001). Fat quality had
an impact on water consumption, respectively. SFA and
MUFA fed mice showed reduced water consumption
(P < 0.01) compared to PUFA fed mice (Table 3).
Influence of fatty acids on portal endotoxin, hepatic
MyD88 and intestinal tight junctions
We show that portal endotoxin levels were increased
in mice fed the diets enriched with fatty acids compared
to control mice (P < 0.05, Figure 2A). Fat quality, here
SFA and MUFA diets, increased endotoxin concen-
tration, respectively (P < 0.001, Figure 2A). MyD88 is
known as a marker for endotoxin translocation and the
subsequent stimulation of TNF-α [26]. In our study
MyD88 was not influenced by fat quantity or quality
neither on mRNA (Figure 2B) nor on protein level (data
not shown).
In previous studies, we and others could show that a
decreased expression of the tight junction proteinA
C
Figure 3 Dietary saturated and monounsaturated fatty acids seem no
analysis of the 5-HT content and the TPH1 mRNA expression in the duode
duodenum and quantitative analysis of protein expression are shown (C/D
compared to SFA. Means ± SEM, n = 5. Abbreviations: C, control; SFA, saturated
fatty acids; 5-HT, serotonin; 5-HT3AR, 5-HT receptor 3A; SERT, 5-HT reuptake traoccludin in the small intestine is associated with an in-
creased translocation of endotoxin from the small intes-
tine to the liver [27,28].
Here, we show a decreased occludin protein concen-
tration in the duodenum (P < 0.01, Figure 2C) and the
ileum (P < 0.05, Figure 2E) of mice fed the diets enriched
with fatty acids. In addition, claudin-1 protein levels
were reduced in the duodenum (P < 0.05, Figure 2D) but
not in the ileum (Figure 2F) of mice fed the diets
enriched with fatty acids.
Effect of fatty acids on the serotonergic system
5-HT, which is produced at high amounts in the GI
tract, is involved in the regulation of intestinal motility
and possibly permeability [7,17,29]. Hence, we quanti-
fied 5-HT concentration, TPH1 mRNA expression, as
well as 5-HT transporter (SERT), and 5-HT3AR protein
content in the duodenum of mice (Figure 3). We found
no significant change of intestinal 5-HT neither in fatty
acid enriched diet fed mice in comparison to control mice
nor between the diverse fatty acid groups (Figure 3A).
Similarly, TPH1, the rate limiting enzyme during 5-HT
synthesis, showed a noticeable, but not significant
effect neither regarding the fatty acid enriched diets in
comparison to control mice nor the fatty acid quality
(Figure 3B). SERT protein expression was not affectedB
D
t to influence the intestinal serotonergic system. Quantitative
num (A/B). Representative western blots of SERT and 5-HT3AR in the
). aP < 0.05 ANOVA result for effect of different diets compared to C; b
fatty acids; MUFA, monounsaturated fatty acids; PUFA, polyunsaturated
nsporter; TPH1, Tryptophanhydroxylase 1.
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control diet or influenced by fatty acid quality, respect-
ively (Figure 3C). However, SERT protein expression
was nearly twice as high in mice fed a diet enriched





Figure 4 Effect of TRP supplement and diets enriched with fatty acids
proteins. Portal endotoxin (A/E), triglycerides (B/F) and tight junction protein
diet. aP < 0.05 ANOVA result for effect of the diets compared to C; bP < 0.05 c
MUFA. Means ± SEM, n = 5–6. Abbreviations: C, control; TRP, Tryptophan; SFA,(Figure 3C). A similar but not significant tendency was
shown for the 5-HT3AR protein expression (Figure 3D).
Motility, although slightly elevated in mice fed the fatty
acid enriched diets, was not significantly influenced by





on portal endotoxin, hepatic triglycerides and tight junction
concentrations (C/D) were analyzed in mice fed TRP and SFA or MUFA
ompared to C + TRP; cP < 0.01 compared to SFA, cP < 0.05 compared to
saturated fatty acids, MUFA, monounsaturated fatty acids.
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and the serotonergic system
Interestingly, our second experiment feeding TRP as a
supplement showed a reduction (P < 0.01) of the SFA in-
duced increase (P < 0.05) in portal endotoxin concentration
(Figure 4A,E). However, the elevated hepatic triglycerides
and the significant loss of the tight junction proteins oc-
cludin and claudin-1, in the duodenum after feeding the
SFA enriched diet, was not normalized by TRP (Figure 4B,
C, D). Similarly, TRP supplement neither influenced food
nor water intake in SFA enriched or control diet fed mice.
In mice fed with the MUFA enriched diet TRP supplement
had similar effects as shown for the SFA diet, reducing
portal endotoxin (P < 0.05) but not hepatic triglyceride
concentration (P < 0.05)(Figure 4E, F). Motility slightly
increased in control mice after feeding TRP (Table 4).
Discussion
Diets enriched with particular fatty acids such as SFA
and MUFA, but not PUFA, cause the induction of fatty
liver disease in C57BL/6 mice when compared to mice
fed with a control diet. We selected this voluntary feed-
ing model, instead of genetic models of obesity or forced
feeding models because our model reflects best the
human situation wherein primarily eating habits, besides
genetic constellations cause NAFLD and obesity. More-
over, our approach allows the comparison of the effect
of fatty acid quantity and quality on liver pathology,
intestinal permeability and the serotonergic system.
Among the three diets, the SFA enriched diet had the
most pronounced effects on fatty liver disease and
weight gain, followed by the MUFA enriched diet. Earlier
studies also reported that SFA and MUFA, but not
PUFA induce changes in body weight and composition
[30,31]. On the other hand MUFA are thought to ameli-
orate the plasma lipid profile in humans [32]. However,
the underlying mechanisms still remain unclear [33].
The fact that PUFA ameliorate plasma triglycerides as
well as low-density lipoprotein and high-density lipoprotein
cholesterol in humans [34] underlines our findings that
PUFA fed animals show only minor increase in triglycerides
and hepatic fat accumulation in contrast to SFA and MUFA
fed animals. One reason could be that PUFA expedite
weight regulating or anti-inflammatory effects, for exampleTable 4 Effect of tryptophan in combination with fatty acids
Diets C
n 6
Food intake (kcal/wk) 80.18 ± 1.52
Water intake (ml/wk) 26.42 ± 0.88
Intestinal motility (distance in cm) 12.09 ± 3.37
Means ± SEM from n = 6 mice per group. aP < 0.05 compared to C, bP < 0.05 compar
TRP, tryptophan.in our study the slight up-regulation of the SERT reducing
extra-cellular 5-HT levels. Furthermore, we cannot exclude
that PUFA fed mice were still in their hyperphagic phase
[35,36].
In contrast to our findings, another study showed
an up-regulation of liver triglycerides by PUFA. Using a
high-fat feeding model over 3 weeks in rats (n = 6; 59%
fat-derived calories (PUFA = safflower), 23% carbohydrate-
derived, 18% protein-derived) [37]. The difference might
be due to the high amounts of PUFA that were fed in this
study.
Most interestingly, the effects of fatty acid enriched
diets on fatty liver disease and body weight may be par-
tially related to the function of the gastrointestinal (GI)
barrier. This is documented by our findings that fatty
acid enriched diets reduced the protein expression of
occludin in the small intestine what seems to result in
enhanced endotoxin levels in the portal blood. Similarly,
models of fatty liver disease, e.g. induced by dietary fruc-
tose or by lack of leptin showed that occludin protein
expression is decreased and portal endotoxin levels are
elevated in the small intestine [7,38]. For example Brun
et al. (2007) reported that loss of the tight junction pro-
teins occludin and zonula occludens 1 is associated with
the development of NAFLD in ob/ob mice [11]. Taken
together, there is increasing experimental evidence that
the GI barrier plays a critical role in the pathogenesis of
NAFLD [11,27,39]. We support this data showing ele-
vated portal endotoxin concentration, what may be the
trigger for the slightly but not significantly elevated
MyD88 mRNA concentration in the liver of mice fed
with the SFA enriched diet.
Furthermore, 5-HT seems to directly affect the expres-
sion of tight junction proteins in mammary gland cells
[40]. We cannot support these in vitro findings since it
is highly speculative to associate the reduced intestinal
tight junction expression with the slightly but not signifi-
cant increased intestinal 5-HT and TPH1 concentrations
after feeding SFA and MUFA enriched diets. Another
study reported a fibrogenic role for 5-HT in the liver by
showing that 5-HT receptor antagonists attenuate the pro-
liferative and enhance the apoptotic properties of hepatic
stellate cells [41]. Indeed, we saw ballooning cells known
as a pre-stage before the development of fibrosis in liveron food and water intake as well as motility
C + TRP SFA SFA + TRP
6 6 6
91.98 ± 2.10 98.58 ± 1.23a 117.88 ± 4.24a,b
27.21 ± 2.44 18.68 ± 0.77a 21.02 ± 1.22b
18.93 ± 1.32a 16.41 ±1.63 17.12 ± 2.12
ed to C + TRP. Abbreviations: C, control; SFA, saturated fatty acids;
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MUFA fed mice. However, if these findings are related to
elevated hepatic serotonin levels needs to be proofed.
The tight junction protein expression was reduced in
the duodenum and ileum after feeding the fatty acid
enriched diets. Consequently, our data underlines a diet-
induced GI barrier dysfunction and subsequent develop-
ment of NAFLD.
Interestingly, our data suggest that endotoxin levels may
be manipulated by TRP treatment. We clearly showed that
SFA enriched diet with TRP supplement does ameliorate
portal endotoxin concentration, but not, as expected,
hepatic triglycerides or tight junction proteins. Here, TRP
may lead to an increase of the enzyme indoleamine
2,3-dioxygenase in the intestinal epithelia that may cause
growth arrest of several tryptophan-dependent microor-
ganisms and is involved in repair processes within the
epithelial barrier [42]. In contrast to the latter findings, it
was shown that a high-fat and high-fructose diet supple-
mented with TRP aggravates hepatic steatosis in mice [43].
Nevertheless, it is not clear if this is a result of the possibly
elevated 5-HT levels in the intestine [20,21] or due to a
shift towards the pro-inflammatory tryptophan 2,3-dioxy-
genase/nicotinamide adenine dinucleotide pathway in the
liver [25]. The underlying mechanisms for the here shown
effects of TRP in combination with a high-fat diet remain
unclear and need further analysis.
Conclusion
In conclusion, our data clearly demonstrated that dietary
fat components such as SFA and to a lesser extend
MUFA are capable of modulating the intestinal barrier
and liver fat accumulation but not necessarily the sero-
tonergic system. Increased GI permeability may lead to
an enhanced translocation of bacterial endotoxin to the
liver and finally liver damage. Future prospects will be to
elucidate the mechanisms by which SFA and MUFA, but
not PUFA, cause the development of NAFLD.
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